Cellectis SA (ALCLS.PA) (Alternext:ALCLS.PA) announces that it has entered into an exclusive license agreement with The Ohio State University, through the Ohio State Innovation Foundation, to develop and commercialize chimeric antigen receptor (CAR) technology targeting multiple myeloma cells.
The CAR technology licensed to Cellectis is related to CS1, an antigen that is over-expressed in multiple myeloma cells. Cellectis intends to pursue the development of a CS1 CAR T-cell program for this targeted indication.
I agree with you.....patents to expire, new treatments coming on line. I have tried to sell UTHR for some time. The stock has surprised me for years and keeps rising......UTHR is now tied to Craig Venter to develop transplantable pig organs......... any thoughts??
Seems like more than one company inthe PAH market. The PAH population is limited and appears to be shrinking. Future of UTHR is with transplantable organs. Is this really going to happen in my lifetime??
Anyone have any insite??
The second full week of the month will bring the annual JPMorgan Healthcare Conference in San Francisco, in which many companies release product and/or financial news. First thing on the morning of Jan. 12, Celgene (NASDAQ:CELG) is set for a presentation. Typically the firm offers a preview of Q4 results and guidance for the year, and sometimes for subsequent years.